Seokoh Moon

Seokoh Moon

Auto-generated profile, based on publicly available information

Seokoh Moon

Department of Molecular Microbiology and Immunology, Division of Biology and Medicine, Brown University, Providence, RI 02912, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
BKByoungjae Kong
Byoungjae Kong
SMSeokoh Moon
Seokoh Moon
YKYuna Kim
Yuna Kim
PHPaul Heo
Paul Heo
YJYounghun Jung
Younghun Jung
Dae-Hyuk KweonDae-Hyuk Kweon
Dae-Hyuk Kweon
Membrane-disrupting agents that selectively target virus versus host membranes could potentially inhibit a broad-spectrum of enveloped viruses, but currently such antivirals are lacking. Here, we develop a nanodisc incorporated with a decoy virus receptor that inhibits virus infection. Mechanistically, nanodiscs carrying the viral receptor sialic acid bind to influenza virions and are co-endocytosed into host cells. At low pH in the endosome, the nanodiscs rupture the viral envelope, trapping viral RNAs inside the endolysosome for enzymatic decomposition. In contrast, liposomes containing a decoy receptor show weak antiviral activity due to the lack of membrane disruption. The nanodiscs inhibit influenza virus infection and reduce morbidity and mortality in a mouse model. Our results suggest a new class of antivirals applicable to other enveloped viruses that cause irreversible physical damage specifically to virus envelope by viruses’ own fusion machine. In conclusion, the lipid nanostructure provides another dimension for antiviral activity of decoy molecules.

28 February 2025 in Science Advances
Verified
Journal Article
Open access
JSJaewon Song
Jaewon Song
LZLi Zhang
Li Zhang
SMSeokoh Moon
Seokoh Moon
AFAriana Fang
Ariana Fang
GWGuoxun Wang
Guoxun Wang
SLSanghyun Lee
Sanghyun Lee
Plasma membrane rupture by Ninjurin-1 (NINJ1) executes programmed cell death, releasing large cellular damage-associated molecular patterns (DAMPs). However, the regulation and selectivity of NINJ1-mediated DAMP release remain unexplored. Here, we uncover that murine norovirus (MNoV) strategically co-opts NINJ1 to selectively release the intracellular viral protein NS1, while NINJ1-mediated plasma membrane rupture simultaneously bulk-releases various cellular DAMPs. Host caspase-3 cleaves the precursor NS1/2, leading to NS1 secretion via an unconventional pathway. An unbiased CRISPR screen identifies NINJ1 as an essential factor for NS1 secretion. During infection, NINJ1 is recruited to the viral replication site, where it oligomerizes and forms speckled bodies, directly interacting with NS1. Subsequent mutagenesis studies identify critical amino acid residues of NS1 necessary for its interaction with NINJ1 and selective secretion. Genetic ablation or pharmaceutical inhibition of caspase-3 inhibits oral MNoV infection in mice. This study underscores the co-option of NINJ1 for controlled release of an intracellular viral protein.

15 July 2022 in Journal of Ginseng Research
Verified
Journal Article
Open access
JMJeonghui Moon
Jeonghui Moon
YJYounghun Jung
Younghun Jung
SMSeokoh Moon
Seokoh Moon
JHJaehyeon Hwang
Jaehyeon Hwang
SKSoomin Kim
Soomin Kim
Dae-Hyuk KweonDae-Hyuk Kweon
Dae-Hyuk Kweon
Pseudotyped virus systems that incorporate viral proteins have been widely employed for the rapid determination of the effectiveness and neutralizing activity of drug and vaccine candidates in biosafety level 2 facilities. We report an efficient method for producing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudovirus with dual luciferase and fluorescent protein reporters. Moreover, using the established method, we also aimed to investigate whether Korean Red Ginseng (KRG), a valuable Korean herbal medicine, can attenuate infectivity of the pseudotyped virus. A pseudovirus of SARS-CoV-2 (SARS-2pv) was constructed and efficiently produced using lentivirus vector systems available in the public domain by the introduction of critical mutations in the cytoplasmic tail of the spike protein. KRG extract was dose-dependently treated to Calu-3 cells during SARS2-pv treatment to evaluate the protective activity against SARS-CoV-2. The use of Calu-3 cells or the expression of angiotensin-converting enzyme 2 (ACE2) in HEK293T cells enabled SARS-2pv infection of host cells. Coexpression of transmembrane protease serine subtype 2 (TMPRSS2), which is the activator of spike protein, with ACE2 dramatically elevated luciferase activity, confirming the importance of the TMPRSS2-mediated pathway during SARS-CoV-2 entry. Our pseudovirus assay also revealed that KRG elicited resistance to SARS-CoV-2 infection in lung cells, suggesting its beneficial health effect. The method demonstrated the production of SARS-2pv for the analysis of vaccine or drug candidates. When KRG was assessed by the method, it protected host cells from coronavirus infection. Further studies will be followed for demonstrating this potential benefit.

1 March 2018 in Process Biochemistry
Verified
Journal Article
Closed access
SMSeokoh Moon
Seokoh Moon
BKByoungjae Kong
Byoungjae Kong
YJYoung-Hun Jung
Young-Hun Jung
YKYuna Kim
Yuna Kim
SYSeokhyeon Yu
Seokhyeon Yu
Dae-Hyuk KweonDae-Hyuk Kweon
Dae-Hyuk Kweon